Long-term effects of octreotide therapy on in-stent restenosis

详细信息    查看全文

• 作者：S. Hurkan Kursaklioglu ; Atila Iyisoy ; Basri Amasyali ; Cem Barcin ; Sedat Kose ; Turgay Celik ; Ayhan Kilic ; Cengiz Ozturk and Ertan Demirtas
• 关键词：In ; stent restenosis ; Octreotide ; Neointimal hyperplasia
• 刊名：Heart and Vessels
• 出版年：2003
• 出版时间：July 2003
• 年：2003
• 卷：18
• 期：3
• 页码：130-135
• 全文大小：196 KB

文摘

The purpose of this study was to assess the long-term effects of octreotide therapy on in-stent restenosis at 6-month follow-up coronary angiography and the clinical events after stenting. A randomized, double-blind, placebo-controlled trial was conducted to assess the effects of octreotide on restenosis after stenting. The patients (n = 148) received either subcutaneous octreotide or placebo 1h before the stenting procedure and then every 8h for 3 weeks. Percent diameter stenosis was interpreted before and after stenting, and on a 6-month follow-up coronary angiogram by quantitative coronary angiography. The mean percent diameter stenosis of the octreotide group was significantly lower than that of the placebo group on the 6-month follow-up coronary angiograms (18.8 % ± 14.2 % vs 35.0 % ± 19.2 % , respectively; P = 0.001). The restenosis rate of the octreotide group was statistically lower than that of the placebo group (11.8 % vs 26.4 % , respectively; P 0.05). With regard to major cardiovascular events, there was no significant difference between the octreotide and placebo groups. The administration of octreotide for treatment of in-stent restenosis results in a relatively low long-term angiographic restenosis rate and no significant acute effects on cardiovascular clinical events.